Today, Beactica Therapeutics is setting the pace in the cancer drug development landscape, with a strong focus on leveraging targeted protein degradation to develop novel therapeutics for life-threatening diseases. This position at the forefront of the field, is rooted in Beactica’s unique heritage spanning decades of research and industrial development.
This exceptional track record – in combination with the team's dedication to scientific excellence – showcases Beactica ability to steadily advance its position in the pharmaceutical R&D value chain.
Today, our vision is to become a clinical-stage precision oncology company with a pipeline of breakthrough therapeutics against genetically defined cancers.
Read more about our pipeline here.
Sign up for the Beactica newsletter to receive our latest news and updates